CC
Casdin Capital Portfolio holdings
AUM
$1.1B
1-Year Return
24.98%
This Quarter Return
-13.03%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$4.01B
AUM Growth
+$69M
(+1.8%)
Cap. Flow
+$681M
Cap. Flow
% of AUM
16.99%
Top 10 Holdings %
Top 10 Hldgs %
52.72%
Holding
62
New
7
Increased
9
Reduced
7
Closed
8
Top Buys
| 1 |
MaxCyte
MXCT
|
+$171M |
| 2 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
+$154M |
| 3 |
Absci
ABSI
|
+$89.8M |
| 4 |
Ginkgo Bioworks
DNA
|
+$83.5M |
| 5 |
Pacific Biosciences
PACB
|
+$76.4M |
Top Sells
| 1 |
AMRS
Amyris Inc.
AMRS
|
+$49.1M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$45.3M |
| 3 |
NeoGenomics
NEO
|
+$22.1M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$12.1M |
| 5 |
Clover Health Investments
CLOV
|
+$9.68M |
Sector Composition
| 1 | Healthcare | 91.34% |
| 2 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Foghorn Therapeutics
FHTX
$293M
| $3M | 0.07% |
215,000
-1,216
| -0.6% | -$16.9K |
|
52
Nautilus Biotechnolgy
NAUT
$91M
| $1.38M | 0.03% |
225,000
-275,000
| -55% | -$1.69M |
|
53
Sana Biotechnology
SANA
$828M
| $1.35M | 0.03% |
60,000
| – | – |
|
|
54
Clover Health Investments
CLOV
$1.57B
| – | – |
-726,511
| Closed | -$9.68M |
|
|
55
Fulcrum Therapeutics
FULC
$379M
| – | – |
-1,154,476
| Closed | -$12.1M |
|
|
56
NeoGenomics
NEO
$1.03B
| – | – |
-488,889
| Closed | -$22.1M |
|
57
Sangamo Therapeutics
SGMO
$152M
| – | – |
-550,000
| Closed | -$6.58M |
|
58
Vertex Pharmaceuticals
VRTX
$101B
| – | – |
0
| – | – |
|
|
AMRS
59
DELISTED
Amyris Inc.
AMRS
| – | – |
-3,000,000
| Closed | -$49.1M |
|
|
ZY
60
DELISTED
Zymergen Inc. Common Stock
ZY
| – | – |
-30,000
| Closed | -$1.2M |
|
|
TPTX
61
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| – | – |
-75,000
| Closed | -$5.85M |
|
|
CNST
62
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – |
-1,341,000
| Closed | -$45.3M |
|